Srividya Ravi
26 April 2022
South Centre Research Paper No. 153
This report provides an analysis of patents covering medicines in trials to treat COVID-19. The aim of the report is to support national patent offices and interested parties in developing countries with information that can serve as guidance for the examination of the claims contained in relevant patents or patent applications.
The medicines considered for the patent analysis in this report are remdesivir, ruxolitinib, favipiravir, molnupiravir and nirmatrelvir, and the biotherapeutics tocilizumab, siltuximab and sarilumab.
Full paper: https://www.southcentre.int/research-paper-153-26-april-2022/
QUT Media4th November 2025 The United Kingdom Parliament is considering a bill aimed at making smoking obsolete, which has been
Speaking at the Global Expert Network on Copyright User Rights Symposium on 16 June 2025, Professor Christophe Geiger argues for
On 25 September 2025, Professor Wend Wendland, delivered the 14th Peter Jaszi Distinguished Lecture at American University in Washington D.C..
On September 18, 2025, the Italian Senate definitively approved the country’s first comprehensive framework law on artificial intelligence (AI). The
Por Andrés Izquierdo Durante la segunda semana de agosto, fui invitado a hablar en la Feria Internacional del Libro de
By Andrés Izquierdo AI, Copyright, and the Future of Creativity: Notes from the Panama International Book FairDuring the second week